Stock Ratings / Health Care / CLOV / forecast

FTRE (35) ACHC (37) CELC (36) PSNL (36) ⌘ Pro Terminal →

Clover Health Investments Corp. (Class A) (CLOV) 12-Month Stock Forecast & Price Target Cone

$4.58 -4.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.54

Clover Health Investments Corp. (Class A) (CLOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.43B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.54 (-0.98%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLOV)Realized 20D OHLCV Swing Band: ±10.6%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY CLOV SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.62 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (±10.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.79-6.5% Next Q

Q2 (-2Q)

Grade E$4.48+2.7% Next Q

Q3 (-1Q)

Grade E$4.60-0.4% Next Q

Current

Grade E$4.58-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLOV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLOV currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.51) and Max Pain ($4.81) forces dealer call-delta covering toward $5.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLOV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLOV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CLOV Position Size: $10,000

Shares at $4.58: 2183.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.12

$6,812

$-3,188 (-31.9%)

12M Consensus BaseTarget $4.00

$8,734

$-1,266 (-12.7%)

12M Bull Case BreakoutTarget $5.87

$12,817

+$2,817 (+28.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$6	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLOV)

✓Walkthrough of CLOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.55%▲ ASCENDING TRIANGLE

2026-10-30O $4.53H $4.58L $4.34C $4.58VOL 4.65M

RES: $5.22SUP: $4.17SMA50: $4.51SMA200: $3.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLOV Butterfly Map → + Track CLOV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLOV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLOV)

Health Care Rank #939 of 1016 ⚔️ FTRE vs CLOV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLOV vs. FTRE, ACHC, CELC, PSNL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Clover Health Investments Corp. (Class A) (CLOV) ranks #939 by composite RQD confidence (30/100, grade E) and #224 by equity capitalization ($2.43B). Within this direct 5-issuer industry benchmark cohort, CLOV leads on earnings valuation at N/A trailing P/E, while ACHC leads on capital efficiency and profitability with -24.8% ROIC and — gross margin. ACHC currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with CLOV at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLOV ACTIVE Clover Health Investments Corp. (Class A)	E	30/100	—	—	-29.3%	-4.38%	$2.43B	Benchmark Subject
FTRE Fortrea Holdings Inc.	D-	35/100	—	—	-35.0%	-10.61%	$2.20B	/ftre-vs-clov →
ACHC Acadia Healthcare Company Inc.	D-	37/100	—	—	-24.8%	-0.17%	$2.74B	/achc-vs-clov →
CELC Celcuity Inc.	D-	36/100	—	—	-35.0%	-0.23%	$3.39B	/celc-vs-clov →
PSNL Personalis Inc.	D-	36/100	—	22.7%	-35.0%	-0.47%	$1.70B	/psnl-vs-clov →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801170

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clover Health Investments Corp. (Class A) (CLOV) reported GAAP revenue of $1.92B (+40.3% vs. FY2024 revenue of $1.37B , and +52.7% cumulative change since FY2023) , GAAP net income of -$85.5M, operating cash flow of -$66.9M, and free cash flow of -$69.0M (-307.2% YoY). On the balance sheet, CLOV closed FY2025 with $541.0M in total assets against $0 in total debt (Altman Z-Score: 3.62, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.92B	-$85.5M	-$66.9M	-$69.0M	$541.0M	—
FY2024 (FY)	2024-12-31	$1.37B	-$43.0M	$34.8M	$33.3M	$580.7M	—
FY2023 (FY)	2023-12-31	$1.26B	-$213.4M	-$144.7M	-$144.7M	—	—

3. CLOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Clover Health Investments Corp. (Class A) (NASDAQ: CLOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.58 (-4.38% 1D, market cap $2.43B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLOV ranks #939 in composite RQD confidence.

How does CLOV compare to FTRE and ACHC in the Health Care sector?

Within the Health Care sector (Medical Specialities), CLOV carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.3%. By comparison, FTRE (Fortrea Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, CLOV leads on earnings multiple (N/A) while ACHC leads on capital efficiency (-24.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLOV?

Per CLOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801170), Clover Health Investments Corp. (Class A) generated $1.92B in revenue (+40.3% YoY), -$85.5M in net income, and -$69.0M in free cash flow against $541.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLOV trading relative to its 50-day, 200-day, and 52-week technical levels?

CLOV last traded at $4.58 (-4.38% on volume of 4,070,913 shares), positioning the stock +1.55% above its 50-day simple moving average ($4.51) and +29.38% above its 200-day simple moving average ($3.54). Across its 52-week range of $1.58 to $5.59, CLOV sits at the 74.8% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($4.09 to $5.07).

CLOV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CLOV's 12-month stock price target?

Clover Health Investments Corp. (Class A) (CLOV) carries a 12-month consensus base price target of $4 (-12.7% from $4.58), with a bull-case target of $5.87 and a bear-case floor of $3.12.

Is CLOV stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CLOV E (Strong Sell — SELL) with an RQD Confidence score of 30/100.

Direct Sub-Reports: CLOV RQD Cockpit CLOV 12M Forecast CLOV Earnings & Move CLOV Dividends & DRIP CLOV Insiders & 13F CLOV Whale Options CLOV Profit Sankey CLOV News & Why